News

April 11, 2018

Tenalisib Receives FDA Orphan Drug Status for Treatment of Cutaneous T-cell Lymphoma

News

The U.S. Food and Drug Administration has granted orphan drug status to investigational therapy tenalisib (RP6530) for the treatment of cutaneous T-cell lymphoma, Rhizen Pharmaceuticals announced. In December, the therapy also received ... Read more

April 10, 2018April 10, 2018

Phase 2b Trial of Betalutin in Relapsed Follicular Lymphoma Patients on Track, Nordic Says

News

A Phase 2b trial evaluating Betalutin — a tumor-targeting antibody labeled with a type of radiation — as a third-line therapy for follicular lymphoma patients will conclude a little later ... Read more

April 9, 2018

First Patient Dosed in Phase 3 Trial of Denovo’s DB102 Plus Chemo for High-risk DLBCL

News

A pivotal Phase 3 trial evaluating Denovo Biopharma‘s investigational therapy DB102 (enzastaurin) as an add-on to standard chemotherapy for high-risk diffuse large B-cell lymphoma (DLBCL) has started dosing patients. The ... Read more

April 6, 2018

Bioniz Recruiting Patients for Phase 1/2 Trial of Its Leukemia and Lymphoma Therapy

News

Bioniz Therapeutics is recruiting certain types of leukemia and lymphoma patients for a Phase 1/2 clinical trial of its cancer therapy BNZ-1. The company is seeking people with large granular ... Read more

April 5, 2018April 5, 2018

Telo-HL Scoring Model Developed to Predict Relapse Risk in Hodgkin’s Patients, 3DS Says

News

3D Signatures’ Telo-HL test may be one step closer to clinical use with the development of a scoring model designed to predict the risk of relapse in Hodgkin’s lymphoma patients. The ... Read more

April 4, 2018April 4, 2018

Fatigue Levels Higher, Endurance Lower for Cancer Survivors, Study Finds

News

Adults with a cancer history become fatigued more quickly and show lower endurance compared to adults who have never had cancer, according to a new study. The work, “Fatigability ... Read more

April 3, 2018

Phase 2 Study of DPX-Survivac Combo Doses First Lymphoma Patient

News

A Phase 2 trial testing Immunovaccine‘s combination of DPX-Survivac with chemotherapy and an immune checkpoint inhibitor in diffuse large B-cell lymphoma (DLBCL) has dosed its first participant. The trial is supported by ... Read more

April 2, 2018

Experts Gathered to Discuss Cancer Care, Therapy Updates at NCCN Conference

News

More than 1,700 researchers, clinicians, survivors, patient advocates, and others recently attended the National Comprehensive Cancer Network‘s (NCCN) 23rd Annual Conference held March 22-24 in Orlando, Florida, to talk about cancer ... Read more

March 29, 2018March 29, 2018

CAR T-cell Therapies Deemed Cost-effective for B-cell Cancers in New Report

News

Treatment with chimeric antigen receptor (CAR) T-cell therapies in B-cell cancers, like certain types of lymphoma and leukemia, is associated with an increase in quality-adjusted and overall survival compared ... Read more

March 28, 2018

FDA Examines Anaplastic Large-cell Lymphoma Link to Breast Implants

News

The number of reported cases of breast-implant-associated anaplastic large-cell lymphoma (BIA-ALCL) has risen, according to the U.S. Food and Drug Administration (FDA). The increase in known cases may be ... Read more

Pin It on Pinterest